Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 10/20 | 0.44 |
| ▸ | CDK1 | P06493 | 9/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 9/20 | 0.44 |
| ▸ | PI4KA | P42356 | 2/20 | 0.42 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.42 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25860 | 1.00 | PDPK1 (0.53) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL1982409 | 0.86 | PDPK1 (0.51) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL2402087 | 0.86 | PDPK1 (0.51) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL28144662 | 0.81 | PDPK1 (0.46) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL2306216 | 0.80 | POLA1 (0.46) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL1924592 | 0.80 | PDPK1 (0.59) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL29592683 | 0.80 | PDPK1 (0.59) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL30150749 | 0.80 | PDPK1 (0.51) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL19840 | 0.80 | PDPK1 (0.51) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL16753033 | 0.80 | PNP (0.36) | PDPK1GDACDK2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025041085-A1 | DUAL NUCLEASE SYSTEMS FOR GENE EDITING, METHODS OF PRODUCING AND USING SAME | SPECIFIC BIOLOGICS INC. (CA) | 2025-02-27 | — | — | WO | claimed |
| EP-4240839-A1 | GENE EDITING WITH A MODIFIED ENDONUCLEASE | Specific Biologics Inc. (CA) | 2023-09-13 | — | — | EP | claimed |
| EP-4041249-A1 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | The Scripps Research Institute (US) | 2022-08-17 | — | — | EP | claimed |
| WO-2022097070-A1 | GENE EDITING WITH A MODIFIED ENDONUCLEASE | SPECIFIC BIOLOGICS INC. (CA) | 2022-05-12 | — | — | WO | claimed |
| EP-4743576-A1 | RNA-EDITING OLIGONUCLEOTIDES AND USES THEREOF | Korro Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4713459-A2 | ANTI-VISTA ANTIBODY RNA OR NUCLEIC ACID CONJUGATES (ARCS OR ANCS), COMPOSITIONS CONTAINING, AND THERAPEUTIC USE THEREOF | LIFORDI IMMUNOTHERAPEUTICS, INC. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4704906-A2 | APTAMER-BASED SUSTAINED RELEASE OF THERAPEUTIC AGENTS | The Children's Medical Center Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12565656-B2 | Modulators and modulation of the receptor for advanced glycation end-products RNA | MONASH UNIVERSITY (AU) | 2026-03-03 | — | — | US | disclosed |
| EP-4695398-A1 | FORMULATIONS FOR OLIGONUCLEOTIDE DELIVERY | Alnylam Pharmaceuticals, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4683674-A1 | COMPOSITIONS AND METHODS FOR DELIVERING ANTIBODY OLIGONUCLEOTIDE CONJUGATES FOR EXON SKIPPING | Yale University (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4665854-A1 | TRANSLATION ENHANCING NUCLEIC ACID COMPOUNDS: ASO COUPLED TRANSLATION - UPREGULATION 1 (ACT-UP1) AND USES THEREOF | Arnatar Therapeutics, Inc (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4662318-A1 | PIKFYVE ANTISENSE OLIGONUCLEOTIDES | AcuraStem Incorporated (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2022067398-A1 | TREATMENT OF OPTIC ATROPHY | PYC Therapeutics Limited (AU) | 2022-04-07 | — | — | WO | disclosed |
| EP-3976791-A1 | COMPOUNDS AND METHODS FOR REDUCING FUS EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2022066956-A1 | COMPOUNDS AND METHODS FOR REDUCING APOE EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-3969469-A1 | ANTISENSE OLIGONUCLEOTIDES TARGETING SCN2A RETAINED INTRONS | The Florey Institute of Neuroscience and Mental Health (AU) | 2022-03-23 | — | — | EP | disclosed |
| EP-3969588-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | VIR Biotechnology, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3963077-A1 | TREATMENT FOR SOD1 ASSOCIATED DISEASE | Black Swan Pharmaceuticals, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3955966-A1 | COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | Sarepta Therapeutics, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3946629-A1 | THERAPEUTIC TARGETS FOR ONCOGENIC KRAS-DEPENDENT CANCERS | University Of Massachusetts (US) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565656-B2 | Modulators and modulation of the receptor for advanced glycation end-products RNA | AGER, RNMT, UPF1 | PDPK1 4549/4885GDA 582/4885CDK2 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.